Loading clinical trials...
Loading clinical trials...
The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Octapharma
NCT05935358 · Severe Hemophilia A
NCT06703606 · Severe Hemophilia A
NCT05981274 · Severe Hemophilia A Without Inhibitor
NCT06938542 · Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, and more
NCT07446010 · Severe Hemophilia A
UC Davis Medical Center
Sacramento, California
University of Alberta
Edmonton, Alberta
BC Children's Hospital
Vancouver, British Columbia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions